PAK-104P, a pyridine analogue, reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 369-377

  Vanhoefer, Udo ^a,d   Cao, Shousong ^a   Minderman, Hans ^a   Tóth, Károly ^a   Scheper, Rik J ^b   Slovak, Marilyn L ^c   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4,6 DIMETHYL 1,3,2 DIOXAPHOSPHORINAN 2 YL) 2,6 DIMETHYL 4 (3 NITROPHENYL) 3 PYRIDINECARBOXYLIC ACID 2 (4 BENZHYDRYL 1 PIPERAZINYL)ETHYL ESTER P OXIDE; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PREVENTION; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CYCLIC P-OXIDES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM TRANSPLANTATION; NICOTINIC ACIDS; PACLITAXEL; SARCOMA, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029867130     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Cole, S P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
2. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res., 54: 5902-5910, 1994.
3. Marquardt, D., and Center, M. C. Involvement of vacuolar H+ adenosine triphosphatase activity in multidrug resistance in HL60 cells. J. Natl. Cancer Inst., 83: 1098-1102, 1991.
4. Zaman, G. J. R., Flens, M. J., van Leusden, M. R., De Haas, M., Muelder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F., Broxterman, H. J., and Borst P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl Acad. Sci. USA. 91: 8822-8826, 1994.
5. Slovak, M. L., Ho, J. P., Bhardwaj, G., Kurz, E. U., Deeley, R. G., and Cole, S. P. C. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res., 53: 3221-3225, 1993.
6. Krishnamachary, N., and Center, M. S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res., 53: 3658-3666, 1993.
7. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Alinquist, K. C., Cole, S. P. C., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs Cancer Res., 54: 357-361, 1994.
8. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53: 1475-1479, 1993.
9. Scheffer, G. L., Wijngaard, P. L. J., Flens, M. J., Izquierdo, M. A., Slovak, M. L., Pinedo, H. M., Meijer, C. J L. M., Clevere, H. C. and Scheper, R. J. The drug resistance related protein LRP is a major vault protein. Nat. Med., 1, 578-582, 1995.
10. Cole, S. P. C., Dowries, H. F., and Slovak, M. L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br. J. Cancer, 59: 42-46, 1989.
11. Barrand, M. A., Rhodes, T., Center, M. S., and Twenty-man, P. R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur. J Cancer 29: 408-415, 1993.
12. Cole, S. P. C. Multidrug resistance in small cell lung cancer. Can. J. Physiol Pharmacol., 70: 313-329, 1992.
13. Shudo, N., Mizoguchi, T., Kiyosue, T., Anta, M., Yoshimura, A., Seto, K., Sakoda, R., and Akiyama, S. Two pyridine analogues with more effective ability to reverse multidrug resistance and with lower calcium channel blocking activity than their dihydropyridine counterparts. Cancer Res., 50: 3055-3061, 1990.
14. Yin, M. B., Arredondo, M. A., Guimaraes, M. A., Schöber, C., and Rustum, Y. M. Modulation of the in vitro cytotoxicity of doxorubicin in multidrug resistant cells with and without P-glycoprotein expression. Cell. Pharmacol., 2: 23-28, 1995.
15. Slovak, M L., Hoeltge, G A., Dalton, W S, and Trent, J. M. Pharmacological and biochemical evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res., 48: 2793-2797, 1988.
16. Marsh, W, Sicheri, D, and Center, M. S. Isolation and characterization of Adriamycm-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Res., 46: 4053-4057, 1986.
17. Toth, K., Vaughan, M. M., Slocum, H. K., Arredondo, M. A., Takita, H., Baker, R. M., and Rustum, Y. M. New immunohistochemical "sandwich" staining method for mdrl P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues Am. J. Pathol., 144: 227-236, 1994.
18. Hens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J. L. M., Scheper, R. J., and Zaman, G. J. R. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557-4563, 1994.
19. Skehan, P., Storeng, R., Scudiero, D., Monk, S. A., McMahon, Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Nad. Cancer Inst., 82: 1107-1112, 1990.
20. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, S. D., and Mitchell J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
21. Nooter, K., Van Den Engh, G., and Sonneveld, P. Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells. Cancer Res., 43: 5126-5130, 1983.
22. Speth, P., Linssen, P., Boezeman, J., Wessels, H., and Haanen, C. Quantification of anthracyclines in human hematopoietic cell subpopulations by flow cytometry and high pressure liquid chromatography. Cytometry, 6: 143-150, 1985.
23. Minderman, H., Linssen, P. C. M., Wessels, J. M. C., and Haanen, C. Doxorubicin toxicity in relation to the proliferative state of human hematopoietic cells. Exp. Hematol., 19: 110-114, 1991.
24. Habig, W. H., Pabst, M. J., and Jakoby, W. B. Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J. Biol. Chem., 249: 7130-7139, 1974.
25. Griffith, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem., 106: 207-212, 1980.
26. Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. ATP-dependem transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res., 54: 4833-4836, 1994.
27. Zwelling, L. A., Slovak, M. L., Doroshow, J. H., Hinds, M., Chan, D., Parker, E., Mayes J., Lan Sie, K., Meltzer, P. S., and Trenn J. M. HT1080/ DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase D-reactive drugs despite the presence of a drug sensitive topoisomerase II. J. Natl. Cancer Inst., 82: 1553-1561, 1990.
28. Yin, M. B., Minderman, H., Cao, S., and Rustum, Y. M. Reversal of P-glycoprotein (Pgp) and non-Pgp related multidrug resistance (MDR) in vitro and in vivo by Ro44-5912 and PAK-104P correlated with drug retention and DNA repair. Anticancer Drugs, 5 (Suppl.1): 26, 1994.
29. Twentyman, P. R., Wright, K. A., and Bleehen, N. M. Modification by SDZ PSC-833 of sensitivity to etoposide, cisplatin and taxol in multidrug resistant (MDR) cells with glycoprotein (Pgp)-mediated and MRP-associated phenotypes. Ann. Oncol., 5 (suppl. 5): 326, 1994.
30. Bhalla, K., Huang, Y., Tang, C., Self, S., Ray, S., Mahoney, M. E, Ponnathpur, V., Tourkina, E., Ibrado, A. M., Bullock, G., and Willingham, M. C. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia (Baltimore), 8: 465-475, 1994.
31. Mickisch, G. H., Merlino, G. T., Galski, H., Gottesman, M. M., and Pastan, I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. USA, 88: 547-551, 1991.
32. Versantvoort, C. H. M., Schuurhuis, G. J., Pinedo, H. M., Eekman, C. A., Kuiper, C. M., Lankelma, J., and Broxterman, H. J. Genistein modulated the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells Br. J. Cancer, 68: 939-941, 1993.
33. Müller, M., Meijer, C., Zaman, G. J. R., Borst, P., Scheper, R. J., Mulder, N. H., De Vries, E. G. E., and Jansen, P. L. M. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad Sci. USA, 98: 13033-13037, 1994.